These observations suggest that corilagin alters the manifestation of p-Erk1/2 and p-Akt, mammalian target of rapamycin (mTOR), and Notch1 proteins to control the occurrence and advancement of CCA by targeting the notch signaling pathway. The gene discussed is AKT1; the disease is cholangiocarcinoma.